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Solid PLATFORM or Thin Ice?*Edward Hulten, MD, MPH,yzx Marcelo F. Di Carli, MDyzS ince the introduction of coronary angiographyin 1958 and the near-simultaneous emergenceof exercise stress testing, clinicians have wres-
tled with the controversy of whether it is better to
pursue direct anatomic evaluation of coronary steno-
sis or physiologic evaluation of ischemia in patients
with stable ischemic heart disease (SIHD) (1). Whereas
classical observational studies have concluded that
noninvasive ischemia testing helps to stratify risks
and beneﬁts of medical therapy versus percutaneous
coronary intervention (PCI) (2), modern randomized
trials have not demonstrated such a beneﬁt to diag-
nosing ischemia or performing PCI for SIHD (3,4).
Thus, today the diagnosis and management of SIHD
is in many ways as unclear as ever and perhaps
even more confusing due to the myriad of noninva-
sive testing options, including coronary computed to-
mography angiography (CCTA).
The clinical appeal of coronary angiography
(invasive or noninvasive) is that it provides direct
visualization of plaque morphology and degree of
stenosis. The problem with this approach is that the
percentage of stenosis has poor correlation with cor-
onary blood ﬂow (5) and, consequently, is an inade-
quate surrogate for physiologic signiﬁcance (6).
Anatomic imaging is also wedded with the “oculos-
tenotic” reﬂex and often leads to revascularization
without an apparent prognostic advantage, thereby*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.increasing the cost of care (7–9). On the other hand,
stress imaging for SIHD has imperfect sensitivity and
speciﬁcity (10), thereby leaving cardiologists with the
difﬁcult choice between the sometimes uncertain
clinical signiﬁcance of stress test results versus
anatomic imaging for stenosis with the potential
instant visual gratiﬁcation of opening arterial steno-
sis by PCI.
In 2005, the COURAGE (Clinical Outcomes Utiliz-
ing Revascularization and Aggressive Drug Evalua-
tion) trial did not demonstrate a clinical beneﬁt to
initial PCI versus guideline-directed medical therapy
in SIHD. Additionally, a quality-of-life substudy of
COURAGE showed a small beneﬁt to PCI that was no
longer signiﬁcant after 36 months (11). More recently,
the STICH (Surgical Treatment for Ischemic Heart
Failure) trial (12), the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) trial, and
2 meta-analyses (13,14) have not identiﬁed prog-
nostic beneﬁt from a strategy of initial routine
revascularization for SIHD. One meta-analysis did
report symptom relief after PCI, but no beneﬁt to
mortality, myocardial infarction (MI), or repeat PCI
(15). Some posit that studies of ischemia-driven pa-
tient care and PCI versus medical therapy have
enrolled too many low-risk patients and point to the
initial results of a COURAGE substudy, which was
underpowered but suggested that patients with a
large burden of ischemia (>10% of the left ventricular
myocardium) tended to garner a reduction in death
or MI (p ¼ 0.001 unadjusted; p ¼ 0.08, risk-adjusted)
if achieving a >5% reduction in ischemia (by medical
therapy or revascularization). Unfortunately, a sub-
sequent reanalysis of the COURAGE data found
no apparent beneﬁt to ischemia reduction by add-
ing revascularization to guideline-directed medical
therapy (16). This lack of demonstrated beneﬁt for
ischemia testing to guide management in SIHD in
COURAGE and other trials led to the formation of
the ISCHEMIA (International Study of Comparative
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Approaches) in 2012 (3,4).
On the other hand, the FAME (Fractional Flow
Reserve Versus Angiography in Multivessel Evalua-
tion) trial has demonstrated that a physiologically
guided strategy using fractional ﬂow reserve (FFR)
before coronary intervention was superior to an
angiographically guided approach for reducing a
composite endpoint of death, MI, and coronary
revascularization at 1 year, while reducing the num-
ber of unnecessary PCI and costs (17). However, in
spite of interventional cardiologist expert consensus
recommendation (18) for the use of FFR to guide
revascularization decisions for 50% to 90% coronary
stenosis and multivessel disease, use of FFR in the
NCDR (National Cardiovascular Data Registry) has
been reported as 6.1% of all intermediate lesions that
underwent PCI (19). While recognizing the limitations
and confusion in the published reports, the most
recent American and European guidelines for the
management of SIHD recommend demonstration of
greater than mild ischemia before consideration of
revascularization (20,21).
Can FFR be estimated without coronary catheteri-
zation today at a level of accuracy and reliability
appropriate for individual patient-level decision
making?
The emergence and rapid evolution of CCTA in
the 2000s led to facile noninvasive evaluation of
coronary stenosis with high sensitivity to exclude
signiﬁcant angiographic coronary artery disease
(CAD). The excellent sensitivity of CCTA makes the
test ideal for selected low-intermediate–risk pa-
tients, but the low speciﬁcity of the test has been
its Achilles heel (30% to 42% speciﬁcity compared
with invasive FFR) (22–24). Thus, concern has arisen
that intermediate stenoses, once identiﬁed by
CCTA, may in comparison to alternative diagnostic
methods such as stress imaging, lead to increased
rates of invasive angiography and coronary revas-
cularization of unproven clinical beneﬁt in SIHD
(8,9,25).
In 1822, French engineer Claude-Louis Navier and
Irish mathematician George Gabriel Stokes described
scientiﬁc principles of conservation of mass and mo-
mentum as applied to movement of viscous ﬂuids
that laid the foundation for computational ﬂuid dy-
namics with what eventually would come to be
recognized as the Navier-Stokes equations. Over 150
years later and with the evolution of modern super-
computers, Dr. Charles Taylor and his colleagues from
HeartFlow have reported success with the use of CCTA
data acquired at rest (without the use of adenosine-
stimulated hyperemic challenge as is performed inthe catheterization laboratory) to solve numerous
ﬂuid dynamics equations to noninvasively estimate
lesion-speciﬁc FFR (26). Aside from fractional ﬂow
reserve estimated using computed tomography
(FFRCT), other methods to conduct a “one-stop shop”
evaluation of coronary stenosis include hybrid CCTA–
positron emission tomographic imaging (27), CCTA
combined with stress perfusion (28), and coronary
transluminal attenuation gradients (29). All these
methods have the potential to improve the subpar
speciﬁcity of CCTA, although none has demonstrated
superiority to FFRCT and each poses its own unique
logistical challenges such as increased radiation, scan
time, post-processing work, and cost. Thus, the med-
ical community currently shares a great interest in the
promise and potential of FFRCT.
Despite the enthusiasm for FFRCT, however,
studies to date have shown only modest results with
regard to the incremental value that the FFRCT in-
formation adds to CCTA data. First, the DISCOVER-
FLOW (Diagnosis of Ischemia-Causing Stenoses Ob-
tained Via Non-Invasive Fractional Flow Reserve)
study demonstrated that the addition of FFRCT to
CCTA did not improve the sensitivity to detect le-
sions with invasive FFR <0.8 (91% for CCTA alone
vs. 88% for CCTA þ FFRCT) but did improve the
speciﬁcity of CCTA alone from 40% to 82% (23).
Next, the DEFACTO (Determination of Fractional
Flow Reserve by Anatomic Computed Tomographic
AngiOgraphy) study similarly demonstrated that
sensitivity for detection of stenoses with invasive
FFR <0.8 remained comparable for CCTA alone
versus CCTA þ FFRCT (84% vs. 90%), but speciﬁcity
only marginally improved from 42% to 54%, and the
study did not reach its pre-speciﬁed primary
endpoint for improving speciﬁcity. After this,
HeartFlow reported improvements to the software
algorithm for computation of FFRCT and the NXT
(Analysis of Coronary Blood Flow Using CT Angiog-
raphy: Next Steps) study showed a sensitivity of
94% versus 86% for CCTA alone versus CCTA þ
FFRCT, and speciﬁcity of 34% versus 79%, respec-
tively (24). The NXT study is an encouraging
improvement to CCTA alone, but it demonstrates an
accuracy of FFRCT now approaching single-photon
emission computed tomography or stress echocar-
diography although potentially inferior (without
direct comparison) to stress magnetic resonance
imaging or positron emission tomography (10).
Although randomized controlled trial data have
established invasive FFR as the gold standard for
guiding revascularization, we cannot accept a mathe-
matical estimate of FFR (FFRCT) at prima facie with
equal enthusiasm. Whereas aggregate data show
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tient level, the ability of FFRCT to accurately change
stenosis evaluation should be carefully considered
due to the lack of precision leading to a wide conﬁ-
dence interval. Thus, from DISCOVER-FLOW (23), a
point estimate of FFRCT ¼ 0.8 could have a 95% con-
ﬁdence interval (CI) ranging from 1 (non-ﬂow-limiting)
to 0.57 (severely ﬂow-limiting) (30). By comparison,
for invasive FFR ¼ 0.8, the 95% CI would range from
0.76 to 0.84 (31). Also, FFRCT does not presently
incorporate the inﬂuence of microvasculature or
collateral circulation on coronary ﬂow, and the clinical
impact of this limitation is not known. Currently, there
are no randomized controlled trial outcomes data of
FFRCT that demonstrate an incremental beneﬁt to
CCTA alone or other noninvasive testing, although
multiple studies are ongoing.
OBSERVATIONAL SUBSTUDY OF COST
AND QUALITY OUTCOMES IN THE
PLATFORM TRIAL
The PLATFORM (Prospective Longitudinal Trial of
FFRCT: Outcomes and Resource Impacts) study was a
cohort study designed to test the impact of combined
CCTA þ FFRCT upon the rate of invasive coronary
angiography (ICA) without obstructive stenosis,
costs, and clinical outcomes including death, MI, and
quality of life (QOL). PLATFORM recruited patients
into 1 of 2 strata (noninvasive and invasive) based
upon the type of testing that was planned before
enrollment in the study. The study showed that the
use of CCTA þ FFRCT among those with intended
referral to ICA resulted in a 61% reduction in un-
necessary catheterizations (ICA without obstructive
stenosis) (1). Among patients with planned nonin-
vasive screening, the rates of ﬁnding no obstructive
CAD at ICA were 13% in patients receiving CCTA þ
FFRCT and 6% in those undergoing usual care (1). In
this issue of the Journal, Hlatky et al. (32) report
observational data regarding economic and QOL
implications of testing strategies within PLATFORM.
For patients enrolled in the planned noninvasive
testing stratum, the associated cost was higher with
CCTA þ FFRCT than with usual care including stress
testing, but QOL improved. However, for patients
with planned referral to ICA, the use of CCTA þ
FFRCT was associated with a 32% reduction in cost
but no change in QOL.SEE PAGE 2315Like all cohort data, these observations do not infer
causality, and it is difﬁcult to rectify why QOL was
improved in the noninvasive but not invasivesubgroup, yet cost showed the opposite result. More
importantly, translating these results to clinical
practice might prove challenging. First, clinicians
will not choose between FFRCT and direct referral
to ICA for patient care decisions, especially among
low-intermediate–risk patients with stable symp-
toms, such as those enrolled in PLATFORM. Rather,
the clinical choice would be between CCTA þ FFRCT
and stress testing, which was not used in patients not
receiving FFRCT. The use of stress testing would have
resulted in a similar reduction in the number of un-
necessary ICA, as shown in the planned noninvasive
stratum of PLATFORM and in other studies (33,34),
and even lower costs than testing with CCTA þ FFRCT
would. Thus, the clinical utility of the observed lower
cost with CCTA þ FFRCT versus direct ICA for low-
intermediate–risk patients with SIHD is uncertain.
Second, the study was not powered to demonstrate
an improvement in death or MI, and after unblinded
interventions (PCI or intensiﬁed medical therapy)
with no sham intervention, subjective improvements
in self-reported symptom scales cannot be distin-
guished from placebo effect by the current study
design. Furthermore, the study offers some insight as
to how changes in medical therapy might improve
symptoms (e.g., statins that may reduce ischemia),
but the design unfortunately did not call for reporting
of adjustment of antianginal therapy. Third, all
previous CCTA research has lauded the high nega-
tive predictive value of stenosis <50% by CCTA, so
clinicians should carefully consider the incremental
beneﬁt of using FFRCT versus CCTA alone for non-
obstructive lesions. In fact, a large multicenter
registry (35), a meta-analysis of CTA cohort studies
(36), and also the PROMISE trial (9) demonstrated
that most low-intermediate–risk patients referred to
CCTA with stable chest pain do not have obstructive
CAD. Finally, the recently published SCOT-HEART
(CT Coronary Angiography in Patients With Sus-
pected Angina Due to Coronary Heart Disease) trial
(34) concluded that most stable CAD patients could
be evaluated by CCTA plus exercise stress test, for
less cost and without a 1 to 2 day wait time or need
to send patient data to an outside center for pro-
cessing the FFRCT.
WHAT’S NEXT
Certainly, the PLATFORM cost and QOL analysis adds
to the published data due to the lack of cost data
available and the great interest in the emerging sci-
ence of anatomically derived physiologic metrics
such as FFRCT. The way forward should include ran-
domized trials that evaluate the incremental change
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with or without stress testing, versus stress testing
without CCTA. Additionally, it would be useful to
understand the ability of FFRCT to successfully eval-
uate CCTA acquired in routine practice, which may be
of lower image quality than that obtained at expert
centers in clinical trials. It would also be important to
understand the accuracy of FFRCT derived from CCTA
scans with aggressive radiation dose-reduction such
as 80 kV that have increased image noise. In order to
routinely consider FFRCT, clinicians should be conﬁ-
dent that sending patient data to a data processingcenter for a 1 to 2 day wait and additional signiﬁcant
cost has some value beyond what could be accom-
plished by conventional CCTA or by combining CCTA
with functional testing, such as exercise testing or
stress imaging.
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